Gilead Buys Nimbus Hepatitis Program

07.04.2016 - US drug maker Gilead Sciences is to pay $400 million to Nimbus Therapeutics for its subsidiary Nimbus Apollo and its Acetyl-CoA Carboxylase (ACC) inhibitor program. The ACC program...